Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Up 37.8% in April

Tenax Therapeutics, Inc. (NASDAQ:TENXGet Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 41,900 shares, a growth of 37.8% from the March 31st total of 30,400 shares. Based on an average trading volume of 46,700 shares, the short-interest ratio is currently 0.9 days.

Separately, StockNews.com initiated coverage on Tenax Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock.

TENX traded up $0.08 during trading on Friday, hitting $0.73. The company’s stock had a trading volume of 28,632 shares, compared to its average volume of 37,886. Tenax Therapeutics has a twelve month low of $0.50 and a twelve month high of $2.30. The stock’s fifty day moving average price is $0.66 and its 200-day moving average price is $0.95.

A hedge fund recently raised its stake in Tenax Therapeutics stock. Morgan Stanley raised its holdings in Tenax Therapeutics, Inc. (NASDAQ:TENXGet Rating) by 1,932,400.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 38,650 shares of the specialty pharmaceutical company’s stock after buying an additional 38,648 shares during the quarter. Morgan Stanley owned 0.15% of Tenax Therapeutics worth $80,000 as of its most recent SEC filing. 47.69% of the stock is currently owned by hedge funds and other institutional investors.

About Tenax Therapeutics (Get Rating)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.

See Also

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.